Shafin Tejani often uses the pronoun “we” when discussing his exploits as the founder of more than 20 startups and an investor in dozens more, as in “We’re making a big push into Europe.” Technically he is an executive committee of one, but he is building a team of sorts.
He recently sat down for a meeting in a conference room in the Vancouver offices of BC Diabetes, the practice of Dr. Tom Elliott. While Tejani is investing about $400,000 in a venture with Elliott to develop a genetic test that predicts how diabetics will respond to the drug liraglutide, his real purpose on this day was to get Elliott’s reaction to a product demonstration.
Thirty-nine and preternaturally affable, Tejani, who greets almost everybody as “brother” – partners, friends, the waiter at lunch – had asked a couple of graduate students to demonstrate a device they had designed to test glucose levels. “I saw the market size and the market opportunity,” Tejani says. “Diabetes is global. It’s borderless.”
More at the source: Forbes